Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eszopiclone→

Eszopiclone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
138729-47-2
Molecular formula
C17H17ClN6O3
Molecular weight
388.8 g/mol
Drug class
Non-benzodiazepine hypnoticcyclopyrrolone ligand at the GABAA receptor complex
Mechanism of action
Interacts with GABAA receptor complexes at binding domains associated with benzodiazepine receptors, enhancing inhibitory neurotransmission. The precise mechanism by which eszopiclone produces hypnotic effects is not fully established.
Indications / reported uses
  • Treatment of insomnia characterised by difficulty with sleep onset and/or sleep maintenance in adults; use should be at the lowest effective dose and for the shortest clinically appropriate duration

Sources: US DailyMed — Eszopiclone · NLM MeSH — Eszopiclone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eszopiclone Environmental Risk Assessment (ERA) (the Eszopiclone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.